XtalPi Inc., an AI-based pharmaceutical technology company with an AI-powered platform that twins with existing R&D pipelines, raised an additional $318.8 million through a Series C financing round to bring drug development into the future.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.
South San Francisco-based Annexon, focused on drugs for autoimmune and neurodegenerative disorders, closed on a $100 million Series C financing led by Redmile Group.
London-based Freeline announced the closing of a $120 million extended Series C financing to advance the company’s gene therapy programs, and is considering additional capital fundraising options during 2020.
Post COVID-19: Telemedicine is the new Urgent Care
Consumers, Coronavirus Disease (COVID-19) Pandemic, Doctors, Emergency Rooms, HCPs, Healthcare Communications Agencies, Healthcare Physicians, Hospitals, Market Research, Marketing & Advertising, Medical Professionals, Sales Reps, Series C Financing, Series D Financing, Telemedicine, Urgen Care CentersThe COVID-19 global pandemic, overcrowding of hospitals, the highly contagious virus affecting healthcare professionals and unrelated illnesses has led to a more than 1,000 percent increase of telemed application downloads and memberships. Is this a paradigm shift?
During the fight against COVID-19, the message from venture capital investors to biotechnology companies is mixed.
Kallyope, based in the Alexandria Center for Life Science in New York City, secured $112 million in a Series C financing round that will be used to advance the company’s gut-brain axis field-focused programs into clinical trials.
Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology.